Kornimate/medical-research-clean huggingface dataset:
cognitive behavioural couple intervention therapy for chinese couples with a depressed partner

Conditions: Depression

Summary: understanding depression from a relational perspective maybe more meaningful in chinese culture due to the different values and beliefs among chinese comparing to those of the western cultures. the pi and his associates developed a cognitive behavioural couple therapy model for chinese couples with a depressed partner receiving mental health services in a community mental health centre in hong kong between 2018 and 2019. with consideration of the limitations in a pilot study conducted by the pi, modifications are made in the current study. this study aims to evaluate the effectiveness of a cognitive behavioural couple therapy model for chinese couples with a depressed partner in hong kong. a comparison approach involving cognitive behavioural couple therapy (cbct), emotional focused couple therapy (efct) and a wait-list control group on their short-term and long-term effects, as well as differential benefits will be examined. a set of questionnaires will be filled out by the 135 participants (45 in each arm) before the intervention (t0), after the intervention (t1), and 6-month after the intervention (t2). it is hypothesized that comparing to the control group, participants in cbct and efct conditions will have greater improvements in outcomes at t1 and t2. there will be differential therapeutic effects of cbct and efct on the various outcomes. different mediating effects behind the changes in the outcomes in the two conditions will be examined. the study will contribute to the current literature by evaluating the effectiveness of culturally-attuned cbct and efct. new insights will be added to the current therapeutic approaches for couples with a depressed partner. a sets of questionnaires will be assessed before the intervention (t0), after the intervention (t1), and 6-month after the intervention (t2). it is hypothesized that comparing to the control group, participants in cbct and efct conditions will have greater improvements in outcomes at t1 and t2. also, they may receive differential therapeutic effects of cbct and efct on different outcomes. different mediating effects behind the changes in the outcomes will be examined. the study will contribute to the current literature by evaluating the effectiveness of culturally-attuned cbct and efct. insights may be provide to the current therapeutic approach for couples with depressed partners.


Eligibility criteria:
inclusion criteria: * chinese couples aged 18 to 65 * able to understand cantonese or chinese * one of the couples having a diagnosis of dsm-v major depressive disorder (mdd) exclusion criteria: * neurological disease or damage that would compromise cognitive functioning * suicidal attempts or ideation in the past 3 months
stem cell therapy in autism spectrum disorders

Conditions: Autism Spectrum Disorders

Summary: the purpose of this study was to study the effect of stem cell therapy on common symptoms in patients with autism spectrum disorders


Eligibility criteria:
inclusion criteria: * diagnosed cases of any type of autism spectrum disorders * age above 6 months exclusion criteria: * presence of acute infections such as human immunodeficiency virus/hepatitis b virus/hepatitis c virus * malignancies * bleeding tendencies * pneumonia * renal failure * severe liver dysfunction * severe anemia \[hemoglobin \< 8\] * any bone marrow disorder * space occupying lesion in brain * other acute medical conditions such as respiratory infection and pyrexia

Keywords: autism spectrum disorders stem cells
a study for non-smoker patients with nonsquamous non-small cell lung cancer

Conditions: Non-Small-Cell Lung Cancer

Summary: the purpose of this study is to compare the combination of erlotinib and pemetrexed versus either pemetrexed alone and erlotinib alone, in terms of progression-free survival (time until the objective worsening of the disease) in patients who have never smoked and have locally advanced or metastatic nonsquamous non-small cell lung cancer who have failed a first-line chemotherapy treatment.


Eligibility criteria:
inclusion criteria: * patients with locally advanced or metastatic nonsquamous non-small cell lung cancer * patients must be non-smokers * patients must have at least one measurable lesion * performance status of 0 to 2 on the eastern cooperative oncology group scale * patients must have failed only one prior chemotherapy regimen and must be considered eligible for further chemotherapy following progression of their disease. exclusion criteria: * patients who have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication * patients who have previously received treatment with drugs against the human epidermal growth factor receptors * patients who have previously received treatment with drugs which have similar targets as pemetrexed * patients who have any known significant ophthalmologic abnormalities of the surface of the eye * patients who have a history of severe hypersensitivity reaction to erlotinib or pemetrexed
the efficacy of chlorhexidine gluconate pre - disinfection scrubbing in preventing surgical site infections for hepatectomy patients

Conditions: Liver Tumors

Summary: to test whether pre - disinfection skin scrub with 4% chlorhexidine gluconate is more effective on the reduction of surgical site microbial colonization and subsequent infection than is normal saline.

surgical site infections (ssis) following elective surgical procedures occur most commonly as a result of colonization by the patient's native skin flora . the most common pathogens causing ssis are staphylococcus aureus and coagulase-negative staphylococci , components of normal skin flora . therefore, preoperative disinfection of the surgical site with an antiseptic skin preparation is standard practice before any surgical intervention to decrease skin microbial counts before incision . it is considered an important step in limiting surgical wound contamination and preventing infection. a variety of skin-preparation agents and methods are available for preventing surgical site infections and the techniques for preoperative cleansing of the skin vary among hospitals and surgeons. there is a pressing need to elucidate the effect of cutaneous disinfection with chlorhexidine gluconate ( chg ) in prevention of surgical site infections. many studies demonstrated that comparisons with cutaneous disinfection with povidone-iodine, disinfection with chg before insertion of an intravascular device and for post-infection site care can substantially reduce the incidence of device-related infection . hence, this study aimed to test whether an additional chlorhexidine gluconate scrub followed by a routine disinfection would lower the incidence of surgical site culture and subsequent infection after hepatic resection. this data will show the originality and clinical importance of a cutaneous pre-disinfection scrubbing solution for such risk patients with hepatectomy.

Eligibility criteria:
inclusion criteria: * patient who received elective hepatectomy for liver tumors exclusion criteria: * patients who were younger than 18 years of age * patients who had a history of radiation to the operative sites * patients who received repeat hepatectomy * patients who had a history of allergy to chg, ethyl alcohol or povidone - iodine * patients whose tumors were metastatic cancers * patients who had a preoperative active remote infection

Keywords: pre - disinfection scrubbing solution surgical site culture surgical site infection liver tumors hepatectomy chlorhexidine gluconate
free-residue nutrients for the bowel preparation of colon capsule endoscopy

Conditions: Colorectal Polyps

Summary: colon capsule endoscopy(cce) is a new diagnostic method of colonic lesions.it has advantages of no requirement for sedation and air insufflation.the bowel preparation has a closely relationship with yield of diagnosing diseases.bowel preparation of cce is not only to clean the colon but also to promote capsule propulsion.now there is not an optimal method for cce.

objective: in this study, a new bowel preparation regime of the colon capsule is used.this regime combines free-residue nutrients and polyethylene glycol (peg) to achieve a better preparation quality. methods: participants who underwent a diagnostic colonoscopy examination that demonstrated a colorectal polyps that required endoscopic treatment will be recruited to patients in the study. the first 32 participants receive a traditional low fiber diet two days before the test.then the patients will take 2l polyethylene glycol (peg) at 21:00-23:00 before the test day and 2l peg at 05:00-07:00 on the test day for bowel preparation. the subsequent 30 participants receive two-days free-residue nutrients without other diet before the test.then the patients will take 2l peg at 05:00-07:00 on the examination day for bowel preparation. then they will take 5mg mosapride citrate at 8:00 and ingest the colon capsule at 8:30.0.75l and 0.50l peg are administered as boosters.and the therapeutic endoscopy will be given on the following day.before the therapeutic colonoscopy, the participants will take 2l peg. the colon capsule results will be reviewed by two experienced endoscopists who are blinded to first endoscopy results.

Eligibility criteria:
inclusion criteria: * 18-80 years of age. * underwent a diagnostic oc that demonstrated colorectal polyps that required endoscopic treatment. exclusion criteria: 1. dysphagia/swallowing disorder 2. prior major abdominal surgery of the gastrointestinal tract, known or suspected bowel obstruction 3. cardiac pacemaker/implanted electromedical device 4. pregnant or nursing women 5. any allergy or contraindication to the drugs used in the study. 6. refused to sign a informed consent.

Keywords: bowel preparation colorectal polyps colon capsule endoscopy
litt followed by hypofractionated rt for newly diagnosed gliomas (gcc 20138)

Conditions: Glioma; Glioblastoma; Brain Tumor

Summary: the purpose of this study is to evaluate the treatment regimen of using laser interstitial thermal therapy (litt) and hypo-fractionated radiation therapy to treat patients with newly diagnosed gliomas.

radiation therapy is preferably used as an adjunct to surgery for patients with a newly diagnosed or recurrent glioblastoma. litt offers an alternative to surgical resection, and due to its minimally invasive nature, does not delay initiating radiation therapy. another advantage of litt prior to radiation therapy is the ability to obtain a tissue diagnosis of the tumor prior to initiating radiation therapy.

Eligibility criteria:
inclusion criteria: 1. patients with radiographic evidence of suggestive of a primary high-grade glioma 2. brain mri with contrast demonstrates an enhancing mass within 60 days prior to registration. patient must be deemed a candidate for litt from mri by neurosurgery in order to be eligible. 3. history and physical including neurological exam within 30 days prior to registration 4. karnofsky performance status ≥50% within 30 days prior to registration 5. age ≥ 18 years old 6. patients must have signed an approved informed consent 7. patients with the potential for pregnancy or impregnating their partner must agree to practice effective contraceptive methods to avoid conception while on study and for 6 months after study completion. 8. female patients of child-bearing potential must have a negative pregnancy test within 28 days prior to study registration. exclusion criteria: 1. patients that are not surgical candidates for stereotactic biopsy or laser ablation 2. patients with impaired cardiac function or clinically significant cardiac diseases, including any of the following: * history or presence of serious uncontrolled ventricular or significant arrhythmias. * any of the following within 6 months prior to registration: myocardial infarction, severe/unstable angina, coronary artery bypass graft, congestive heart failure, cerebrovascular accident, transient ischemic attack , pulmonary embolism 3. infratentorial tumor or evidence of leptomeningeal spread 4. inability to undergo a mri 5. pregnant or breast-feeding women

Keywords: laser interstitial thermal therapy brain tumor radiotherapy proton therapy glioma
peripheral registry of endovascular clinical outcomes "the prime registry"

Conditions: Peripheral Arterial Disease; Peripheral Vascular Disease; Critical Limb Ischemia

Summary: the prime registry is a multi-center, observational study designed to evaluate immediate and long-term outcomes (36 months) of endovascular revascularization in patients with critical limb ischemia (cli) and advanced peripheral artery disease (pad).

the peripheral registry of endovascular clinical outcomes (prime registry) represents the collaborative effort among seven centers across the us with the goal of reaching 10 sites globally. prime explores all aspects of advanced peripheral arterial disease (pad) and critical limb ischemia (cli) care including the collection of comprehensive clinical, diagnostic, procedural, and follow-up data for three years following an index endovascular procedure. data collection activities began in january of 2013 with the goal of collecting data on 1500 subjects. analysis of this multi-site registry will produce generalizable findings that describe the clinical epidemiology and management practices of advanced pad and cli patients.

Eligibility criteria:
inclusion criteria: * patients who are to receive or have received lower extremity endovascular intervention * rutherford iii-vi classification * ability to provide informed consent within 30 day prior to 60 days post index endovascular intervention. * ability to follow up at enrollment site. exclusion criteria: * inability or unwillingness to consent for participation in the registry.

Keywords: prime pad pvd observational cli prime registry
the correlation between cotinine and postoperative acute and chronic pain after hysterectomy

Conditions: Chronic Pain, Acute Pain, Cotinine, Hysterectomy

Summary: it is known that there is an association between smoking and acute/chronic pain. but it is so difficult to assess this relation with asking questions to the patients in the preoperative period. because of that we want to measure the levels of the cotinine in the urine and later assess the correlation with acute and chronic pain in hysterectomy patients.

it is well-known that smoking is very common in the public. the chronic pain after hysterectomy is 20-40%. the open abdominal hysterectomy ratio is 75% of all hysterectomy operations in our country. we know that the reasons of postoperative acute and chronic pain is multifactorial. one of them is smoking which affects the postoperative pain. the best way of measuring the level of cotinine is assesing the urine of the patient. we collect the first urine after induction. in this study, we aimed to investigate the correlation between the levels of urine cotinine and the acute and chronic postoperative pain in hysterectomy patents.

Eligibility criteria:
inclusion criteria: * asa i-ii * open abdominal hysterectomy patients exclusion criteria: * chronic pain * chronic pain killer users * axis i psychiatric disease * liver disease * renal disease * drug allergy
clinical and pathological characteristics as prognostic factors in locally advanced cervical cancer

Conditions: Cervical Cancer

Summary: locally advanced cervical cáncer continues to be a public health problem in emergent economies, even though treatment is very well standardized, recurrence rate is still high, making necessary to evaluate prognostic clinical and pathological factors. the aim of this study is to evaluate clinical and pathological prognostic factor in terms of treatment outcomes, disease-free survival (dfs) and overall survival (os) in a retrospective cohort of patients with lacc treated with standard chemoradiotherapy in a reference center in méxico.

this is a retrospective study, the data were obtained from clinical files of cervical cancer patients with clinical stages ib2-iva(figo2009) treated at the instituto nacional de cancerología in mexico city from january 2005 to december 2014. a total of 1954 patients with lacc confirmed by pathology, clinical exams and computed tomography scan (ct) were identified. demographic, clinical, pathological and follow-up as well as survival status of all patients was recorded. treatment outcome was classified as complete response if the patient had no signs of tumor activity after 6 months of finishing treatment, persistence of disease was defined if tumor could be identified after treatment or before six months of treatment termination, progression was defined if tumor growth occurred or metastatic disease appeared. disease-free survival (dfs) was defined as the period between finishing treatment and the occurrence of relapse, which was confirmed by pathological study and/or ct. overall survival (os) was defined as the time period between diagnosis and death or date at last visit. quantitative variables were described with central tendency and dispersion measures and analyzed with student's t or mann-whitney u test. normality was determined with shapiro-wilk's test, chi-squared for categorical comparisons between groups, kaplan-meir with the log-rank test for survival analysis were performed. the multivariate analysis was performed using cox proportional hazard regression model. statistically significant differences were defined as a p value \<0.05. statistical analyses were performed using ibm spss, version 23 (ibm corp., armonk, n.y., usa).

Eligibility criteria:
inclusion criteria: * patients with cervical cancer clinical stage ib2-iva * treated with concomitant chemoradiotherapy exclusion criteria: * rare histologies such gastric type adenocarcinoma, neuroendocrine or clear-cell carcinoma * incomplete treatment or not treated with chemoradiotherapy * two primary malignancies * insufficient data for analysis.

Keywords: locally advanced cervical carcinoma prognostic factors
chinese registry of assisted embolization for unruptured wide necked intracranial aneurysm using lvis stent

Conditions: Self Efficacy; Medical Device Complication

Summary: this study aims to investigating the efficacy and safety of low profile visualized intraluminal support (lvis) stents for the treatment of unruptured intracranial saccular aneurysms.

this study is a prospective multi-centre observational single-arm clinical trial, aiming to investigating the efficacy and safety of low profile visualized intraluminal support (lvis) stents combined with coils for the treatment of unruptured intracranial saccular aneurysms. as the protocol, clinical follow-up at 30 days (±7 days) after procedure, dsa or mra follow-up at 6 months (±30 days) after procedure, and clinical follow-up at 1 year (±30 days) after procedure was conducted for each patient. the primary end-points include major adverse events (cerebral infarct and death) in 30 days post-procedure, complete occlusion rate at 6 months (180±30d) follow-up. the secondary end-points were immediate technical success (successful device placement) rate, immediate complete occlusion rate, recurrence rate at 6 months (180±30d) follow-up and in-stent stenosis or obliteration rate at 6 months (180±30d) follow-up. duration of this study is 2 years.

Eligibility criteria:
inclusion criteria: * patients meeting all the following criteria will be enrolled: 1. patients of the age 18-75 years old. 2. patients diagnosed with unruptured intracranial saccular aneurysms via cta, mra or dsa. 3. patients treated with lvis stents combined with coils. 4. patients willing to follow the clinical trial instructions and receive follow-up assessment. 5. patients accepting to participate to the study and sign the consent forms. exclusion criteria: * patients meeting any following criterion will be excluded: 1. patients without proper artery approach. 2. patients with avm. 3. patients with a fusiform or dissecting aneurysm. 4. patients with a recurrent aneurysm. 5. patients treated with a lvis stent without coils. 6. patients in poor clinical status, with mrs ≥4. 7. patients with life expectancy less than 12 months. 8. patients participated in other clinical trial, while has not reach the primary endpoint. 9. patients can not accept anti-platelet regimen. 10. patients allergic to contrast agent or intolerable. 11. patients whom the researchers consider should not participate in or continue this clinical trial.

Keywords: lvis stents intracranial aneurysm unruptured aneurysm wide-necked aneurysm
nucleus hybrid l24 extended duration post approval study

Conditions: Hearing Loss

Summary: this post approval study evaluates the long term safety and efficacy of the nucleus hybrid l24 implant system in a group of already implanted recipients.

the hybrid l24 implant system (p130016) was the subject of a pivotal clinical trial (ide g070191) from 2007 through 2012. data on the 50 subjects enrolled in the study, in support of safety and efficacy of the device, was submitted in june 2013 as part of premarket approval (pma) #130016. as a condition of approval, march 20, 2014, a post-approval study was designed to monitor the long-term (5 years postactivation for each subject) safety and effectiveness of the device in this existing cohort of implanted subjects was designed.

Eligibility criteria:
inclusion criteria: - recipients who were implanted with the hybrid l24 as part of the original pivotal ide study exclusion criteria: * recipients who withdrew or were terminated from the l24 pivotal ide study * recipients who were re-implanted and no longer have a nucleus hybrid l24 implant
effect of repaglinide on postprandial lipemia in type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in the united states of america (usa). the aim of this trial is to compare the effect of repaglinide on postprandial lipemia in subjects with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * newly diagnosed patients with type 2 diabetes currently treated with diet and exercise alone (hba1c below 10%) * subjects with type 2 diabetes treated with sulphonylurea (hba1c below 8.5%) * males or non-pregnant, non-lactating females * subjects should have normal renal function exclusion criteria: * type 1 or other specific causes of diabetes * marked symptomatic diabetes * uncontrolled treated/untreated hypertension * known or suspected allergy to the trial products or related products